|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net loss | |||||
| Adjustments to reconcile Net loss to net cash provided by (used in) operating activities: | |||||
| Provision for credit loss | |||||
| (Gain) loss on right of use assets | |||||
| Gain on sale of property and equipment | |||||
| Equity-based compensation and common stock payments | |||||
| Depreciation and amortization | |||||
| Amortization-debt issuance costs and investment discount | |||||
| Amortization-debt issuance costs | |||||
| Amortization-investment discount | |||||
| Total amortization-debt issuance costs and investment discount | |||||
| Amortization of payment-in-kind interest | |||||
| Equity-based compensation | |||||
| Non-cash lease expense | |||||
| Loss on extinguishment of debt | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Medical expenses payable | |||||
| Accounts payable and accrued expenses | |||||
| Accrued compensation | |||||
| Lease liabilities | |||||
| Payment-in-kind interest | |||||
| Net cash provided by (used in) operating activities | |||||
| Investing Activities: | |||||
| Purchase of business, net of cash received | |||||
| Asset acquisition, net of cash received | |||||
| Purchase of investments | |||||
| Sale of property and equipment | |||||
| Maturities of investments | |||||
| Sale of business | |||||
| Acquisition of property and equipment, net | |||||
| Net cash provided by (used in) investing activities | |||||
| Financing Activities: | |||||
| Repurchase of noncontrolling interest | |||||
| Proceeds from long-term debt | |||||
| Debt issuance costs | |||||
| Repayment of long-term debt | |||||
| Issuance of common stock | |||||
| Common stock issuance costs | |||||
| Payment of employment taxes related to release of restricted stock | |||||
| Proceeds from exercise of stock options | |||||
| Contributions from noncontrolling interest holders | |||||
| Equity repurchase | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for interest | |||||
| Supplemental non-cash investing and financing activities: | |||||
| Acquisition of property in accounts payable | |||||
| Purchase of business in accounts payable | |||||
| Debt issuance costs in accounts payable | |||||
| Reconciliation of cash, cash equivalents and restricted cash as shown in the statement of cash flows: | |||||
| Cash and cash equivalents | |||||
| Restricted cash in other assets | |||||
Loading...